Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

615
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
615
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

764
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
764
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

661
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
661
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

77
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
77

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Upping the "Plex": Whole Slide, Automated 14-Color Multiplex Immunofluorescence Staining of the Tumor Microenvironment in Paraffin-Embedded Tissue.

Laboratory investigation; a journal of technical methods and pathology·2026
Same author

Pain and scrotal involvement are associated with misdiagnosis in extramammary Paget disease: A retrospective cohort study.

Journal of the American Academy of Dermatology·2026
Same author

AstroID resource: a scalable, relational database structure for longitudinal biomarker discovery.

Journal for immunotherapy of cancer·2025
Same author

Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI).

Journal for immunotherapy of cancer·2025
Same author

PD-L1-Negative Macrophages Are Associated with Poor Outcomes and High-Grade Immune-Related Adverse Event Development in Patients with Melanoma Receiving Anti-PD-1 Immunotherapy.

The Journal of investigative dermatology·2025
Same author

A Nationwide Survey of Dermatology Faculty and Mentors on Their Advice for the Dermatology Match Process.

Cutis·2025

Related Experiment Video

Updated: Apr 11, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

PD-1/PD-L1 inhibitors.

Joel Sunshine1, Janis M Taube2

  • 1Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

Current Opinion in Pharmacology
|June 7, 2015
PubMed
Summary
This summary is machine-generated.

Immuno-oncology checkpoint inhibitors targeting PD-1/PD-L1 pathways are revolutionizing cancer treatment. These therapies rebalance the host-tumor interaction, leading to significant tumor regressions in various advanced cancers.

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.1K

Related Experiment Videos

Last Updated: Apr 11, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.1K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Tumors can exploit physiological immune checkpoints for immune evasion, disrupting the balance between tumor growth and host immune surveillance.
  • The programmed cell death protein 1 (PD-1) and its ligand (PD-L1) pathway is a critical checkpoint that tumors utilize to suppress anti-tumor immune responses.

Purpose of the Study:

  • To review updated clinical trial response data for PD-1/PD-L1 checkpoint inhibitors.
  • To discuss recent Food and Drug Administration (FDA) actions concerning this class of immunotherapeutic agents.
  • To summarize findings on the predictive value of PD-L1 expression for treatment response.

Main Methods:

  • Review of early-phase clinical trial data for anti-PD-1 and anti-PD-L1 agents.
  • Analysis of response rates and durability across various tumor types.
  • Examination of studies investigating PD-L1 expression as a biomarker.

Main Results:

  • Anti-PD-1 antibodies (nivolumab, pembrolizumab) and anti-PD-L1 agents (e.g., MPDL3280A, MEDI4736) demonstrate significant anti-tumor activity.
  • These agents have shown efficacy in advanced melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer, and Hodgkin lymphoma.
  • Preliminary data suggest PD-L1 expression may correlate with response, but its predictive role requires further validation.

Conclusions:

  • PD-1/PD-L1 pathway inhibition represents a promising therapeutic strategy, rebalancing host-tumor immunity and inducing durable responses.
  • Continued clinical investigation and biomarker research are essential to optimize patient selection and treatment outcomes.
  • The development of these immunotherapies marks a significant advancement in the treatment of various advanced malignancies.